Cargando…

Economic burden of pneumococcal disease in children in Liguria, Italy

Vaccinations against Streptococcus pneumoniae are included in infant immunization programs globally. However, a substantial burden due to pneumococcal disease (PD) remains. This study aimed to estimate the cost of emergency department (ED) visits and hospitalizations associated with invasive pneumoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amicizia, Daniela, Astengo, Matteo, Paganino, Chiara, Piazza, Maria Francesca, Sticchi, Camilla, Orsi, Andrea, Varlese, Federica, Hu, Tianyan, Petigara, Tanaz, Senese, Francesca, Prandi, Gian Marco, Icardi, Giancarlo, Ansaldi, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Pneumococcal – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621055/ https://www.ncbi.nlm.nih.gov/pubmed/35695748 http://dx.doi.org/10.1080/21645515.2022.2082205

Ejemplares similares

Economic Burden of Pneumococcal Disease in Individuals Aged 15 Years and Older in the Liguria Region of Italy
por: Astengo, Matteo, et al.
Publicado: (2021)

Incidence of Hospitalisation and Emergency Department Visits for Pneumococcal Disease in Children, Adolescents, and Adults in Liguria, Italy: A Retrospective Analysis from 2012–2018
por: Astengo, Matteo, et al.
Publicado: (2022)

Lowering the recommended age for the free and active offer of influenza vaccination in Italy: clinical and economic impact analysis in the Liguria region
por: Trucchi, Cecilia, et al.
Publicado: (2020)

Who Is at Higher Risk of SARS-CoV-2 Reinfection? Results from a Northern Region of Italy
por: Piazza, Maria Francesca, et al.
Publicado: (2022)

Prevalence of multiple sclerosis in Liguria region, Italy: an estimate using the capture–recapture method
por: Ponzio, M., et al.
Publicado: (2021)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

A Retrospective Analysis to Estimate the Burden of Invasive Pneumococcal Disease and Non-Invasive Pneumonia in Children <15 Years of Age in the Veneto Region, Italy
por: Barbieri, Elisa, et al.
Publicado: (2022)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
por: Lytle, Derek, et al.
Publicado: (2023)

Has Clinical and Epidemiological Varicella Burden Changed over Time in Children? Overview on Hospitalizations, Comorbidities and Costs from 2010 to 2017 in Italy
por: Piazza, Maria Francesca, et al.
Publicado: (2021)

The Unknown Health Burden of Herpes Zoster Hospitalizations: The Effect on Chronic Disease Course in Adult Patients ≥50 Years
por: Piazza, Maria Francesca, et al.
Publicado: (2020)

Weight of risk factors for mortality and short-term mortality displacement during the COVID-19 pandemic
por: ASTENGO, MATTEO, et al.
Publicado: (2022)

Regional factors associated with pneumococcal vaccination coverage among U.S. adults with underlying chronic or immunocompromising conditions
por: Liu, Junqing, et al.
Publicado: (2023)

A pediatric case series of invasive pneumococcal disease caused by S.Pneumonia serotype-19A despite full dose vaccination
por: Cura Yayla, Burcu Ceylan, et al.
Publicado: (2023)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
por: Hammitt, Laura L., et al.
Publicado: (2023)

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
por: Ishihara, Yasunori, et al.
Publicado: (2023)

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study
por: Haranaka, Miwa, et al.
Publicado: (2023)

The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy
por: Barbieri, Elisa, et al.
Publicado: (2022)

Pneumonia hospitalizations and mortality in children 3 – 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10)
por: Iliya, Jalo, et al.
Publicado: (2023)

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age
por: Chu, Kai, et al.
Publicado: (2023)

Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy
por: Trucchi, Cecilia, et al.
Publicado: (2016)

A Retrospective Database Analysis to Estimate the Burden of Acute Otitis Media in Children Aged <15 Years in the Veneto Region (Italy)
por: Barbieri, Elisa, et al.
Publicado: (2022)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

Assessment of Knowledge, Attitudes, and Propensity towards HPV Vaccine of Young Adult Students in Italy
por: Trucchi, Cecilia, et al.
Publicado: (2020)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Systemic Sclerosis and Vaccinations: A Register-Based Cohort Study about Seasonal Influenza and Streptococcus pneumoniae Vaccination Rate and Uptake from Liguria Regional Center, Northwest Italy
por: Murdaca, Giuseppe, et al.
Publicado: (2020)

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
por: Mohanty, Salini, et al.
Publicado: (2022)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media
por: Izurieta, Patricia, et al.
Publicado: (2022)

A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population
por: Yunhua, Bai, et al.
Publicado: (2022)

Systemic sclerosis and vaccinations: a three-year register-based cohort study about vaccination rate and uptake from Liguria referral center, northwest Italy
por: Murdaca, Giuseppe, et al.
Publicado: (2022)

Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old
por: Trucchi, Cecilia, et al.
Publicado: (2019)

Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020
por: Guzman-Holst, Adriana, et al.
Publicado: (2021)

Burden and Prevention of HPV. Knowledge, Practices and Attitude Assessment Among Pre-Adolescents and their Parents in Italy
por: Icardi, Giancarlo, et al.
Publicado: (2020)

Cost-Effectiveness of Pneumococcal Vaccination in Adults in Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness
por: Restivo, Vincenzo, et al.
Publicado: (2023)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
por: Sabharwal, Charu, et al.
Publicado: (2022)

The impact of COVID-19 on routine vaccinations in Taiwan and an unexpected surge of pneumococcal vaccination
por: Chiu, Nan-Chang, et al.
Publicado: (2022)

Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease
por: Saiphoklang, Narongkorn, et al.
Publicado: (2022)

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial
por: Pan, Lu-Lu, et al.
Publicado: (2022)

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
por: Nymark, Liv Solvår, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i0apg7usmqdl4tbi15cearv31q